FindMyKOL

Shaker Dakhil, MD

Basic profile

Cancer Center of Kansas

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionWichita, KS · MidwestSpecialtyHematology / OncologyFocusOncology
Active KOLFindMyKOL type: RegionalLatest publication2022Online presenceNot yet checkedPayments2021 onwardNIH funding2001–2018

Shaker Dakhil is an Oncology physician affiliated with Cancer Center of Kansas. OpenAlex indexes 427 publications with 37,397 citations (h-index 81). By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the FindMyKOL directory.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
427publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

37,397citations

Citations across these publications.

81h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
113companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
2NIH grants · 2001–2018

Federally funded research awards.

View funding ↓

Industry payments

113 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Novartis
    Program year20259 paymentsResearch
    $1,243,392
  • Amgen
    Program year20253 paymentsResearch
    $137,571
  • BeiGene
    Program year202511 paymentsResearch
    $38,240
All 359 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    39.9%
    PD-1 inhibitor18.8%
    Pembrolizumab55%Nivolumab45%
    Part B, office-administered≥40 patients
    Platinum-based Drug6.3%
    Oxaliplatin97%Carboplatin3%
    Part B, office-administered≥43 patients

    + 15 more classes in this area

  • Blood & clotting

    28.1%
    Iron, parenteral preparations20.8%
    Ferric carboxymaltose100%
    Part B, office-administered≥41 patients
    Erythropoiesis-stimulating Agent7.3%
    Darbepoetin alfa58%Epoetin alfa42%
    Part B, office-administered≥26 patients
  • Metabolism & gastrointestinal

    17.1%
    Substance P/Neurokinin-1 Receptor Antagonist9.5%
    Aprepitant100%
    Part B, office-administered≥103 patients
    Serotonin-3 Receptor Antagonist7.1%
    Granisetron82%Ondansetron hydrochloride14%Palonosetron hcl4%Ondansetron Hcl0%Ondansetron Odt0%
    Part D + Part B≥84 patients

    + 4 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

2 NIH research awards on record, funded 2001–2018 per NIH RePORTER. The latest:

All 22 award records: search, sort and filter.Explore →

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”